Table 1.
Truly human monoclonal antibodies binding to pdmHA.
| mAb | IGHV | D | J | κ/λ | IGK/LV | J | IGHV mutations |
|---|---|---|---|---|---|---|---|
| (A) mAb GENERATED FROM PLASMABLASTS | |||||||
| I3-15 | 1-69*01 | 3-10 | 6 | κ | 1-39*01 | 2 | 18 |
| I4-109# | 3-33*01 | 4-17 | 4 | λ | 1-40*01 | 2 | 16 |
| I4-112# | 1-2*02 | 6-19 | 3 | λ | 2-8*01 | 2 | 5 |
| I4-115# | 3-20*01 | 3-10 | 4 | κ | 3-11*01 | 1 | 30 |
| I4-128# | 1-69*01 | 5-5 | 5 | κ | 1-5*03 | 2 | 13 |
| I5-7 | 1-69*12 | 3-10 | 3 | κ | 3-15*01 | 1 | 29 |
| I5-24 | 1-69*02 | 3-22 | 4 | κ | 3-20*01 | 2 | 29 |
| I5-52 | 1-18*01 | 3-16 | 6 | κ | 2-30*01 | 1 | 11 |
| I5-69 | 1-69*02 | 5-24 | 4 | κ | 3-11*01 | 5 | 8 |
| V2-1 | 3-30*18 | 1-26 | 6 | κ | 3-20*01 | 1 | 15 |
| V2-2Δ | 4-39*01 | 6-13 | 5 | λ | 1-40*01 | 1 | 33 |
| V2-3Δ | 4-39*01 | 6-13 | 5 | λ | 1-40*01 | 1 | 33 |
| V2-4Δ | 4-39*01 | 6-13 | 5 | λ | 1-40*01 | 1 | 31 |
| V2-7Δ | 4-39*01 | 6-13 | 5 | λ | 1-40*01 | 1 | 21 |
| V2-11Δ | 4-39*01 | 6-13 | 5 | λ | 1-40*01 | 1 | 21 |
| V2-36Δ | 4-39*01 | 6-13 | 5 | λ | 1-40*01 | 1 | 33 |
| V2-38Δ | 4-39*01 | 6-13 | 5 | λ | 1-40*01 | 1 | 34 |
| V2-12 | 4-39*03 | 3-22 | 4 | κ | 4-1*01 | 3 | 34 |
| V4-1° | 1-69*06 | 5-12 | 4 | κ | 3-20*01 | 2 | 29 |
| V4-9 | 1-69*02 | 7-27 | 6 | κ | 3-15*01 | 1 | 34 |
| V4-12 | 3-33*02 | 5-24 | 4 | λ | 3-1*01 | 3 | 31 |
| V4-17* | 4-39*01 | 3-3 | 4 | λ | 1-47*02 | 2 | 19 |
| V4-18° | 1-69*06 | 5-12 | 4 | κ | 3-20*01 | 2 | 23 |
| V4-23 | 1-69*02 | 7-27 | 6 | κ | 1-39*01 | 1 | 34 |
| V4-29 | 1-69*01 | 5-5 | 6 | λ | 2-14*01 | 2 | 28 |
| (B) mAb GENERATED FROM MEMORY B CELLS | |||||||
| I4-1C4 | 1-69*09 | 4-23 | 5 | κ | 3-11*01 | 1 | 23 |
| I4-1F7 | 3-66*01 | 1-26 | 2 | κ | 3-15*01 | 3 | 0 |
| I4-1G8 | 2-70*11 | 2-8 | 6 | λ | 3-1*01 | 1 | 5 |
| I8-1B6 | 1-69*01 | 3-3 | 6 | λ | 2-14*01 | 1 | 22 |
| I14-1D9 | 1-69*04 | 2-15 | 4 | κ | 3-15*01 | 2 | 10 |
| I14-1F8 | 5-51*01 | 5-12 | 6 | κ | 3-11*01 | 5 | 10 |
| I14-2B6 | 4-59*01 | 2-8 | 3 | κ | 1-39*01 | 1 | 19 |
| I14-2B7 | 1-18*01 | 2-8 | 6 | κ | 2-30*01 | 2 | 3 |
| I14-2C5 | 3-30*03 | 6-6 | 4 | κ | 1-6*01 | 2 | 22 |
| V3-1B9 | 3-11*01 | 3-3 | 3 | κ | 1-12*01 | 4 | 10 |
| V3-1C6 | 1-69*01 | 1-1 | 6 | λ | 7-43*01 | 3 | 18 |
| V3-1E8 | 3-33*01 | 1-26 | 4 | λ | 3-25*03 | 3 | 11 |
| V3-1G10 | 1-69*06 | 1-14 | 5 | κ | 3-15*01 | 2 | 25 |
| V3-2C2 | 1-69*06 | 3-9 | 4 | κ | 1-39*01 | 4 | 9 |
| V3-2C3 | 1-69*01 | 3-10 | 5 | κ | 1-5*03 | 2 | 6 |
| V3-2C10 | 1-69*01 | 5-12 | 5 | κ | 1-39*01 | 4 | 21 |
| V3-2E2 | 1-69*01 | 3-10 | 4 | κ | 1-16*02 | 4 | 14 |
| V3-2F10 | 1-69*06 | 3-22 | 4 | κ | 1-5*03 | 1 | 17 |
| V3-2G6 | 1-69*01 | 3-16 | 4 | κ | 3-20*01 | 2 | 18 |
| V3-3B3 | 1-69*01 | 3-10 | 3 | λ | 2-11*01 | 1 | 6 |
| V3-3B6 | 1-69*06 | 2-2 | 6 | κ | 3-20*01 | 1 | 19 |
| V3-3C11 | 1-69*06 | 5-12 | 4 | λ | 2-14*01 | 1 | 9 |
| V3-3D2 | 1-69*01 | 1-14 | 6 | κ | 1-16*-01 | 4 | 21 |
mAbs are named systematically, with the initial letter and number indicating the subject from which it had been generated, with I or V indicating that they were generated from a subject infected (I) or vaccinated (V) with the pdmH1N1 virus. All bound by ELISA to purified recombinant ectodomain of pdmHA and to the pdmH1N1 vaccine, and all but V4-17* also bound to the seasonal 2009/2010 vaccine and to H5 HA (A/Vietnam/1203/2004, Clade 1). mAbs in section (A) were generated from PB, with #indicating those generated from randomly chosen PB that were not sorted for their ability to bind pdmHA; other mAbs in section (A) were generated from PB purified by their binding to pdmHA. mAbs in section (B) were generated from memory B cells purified by their binding to pdmHA. Δ,°Denote clonotypes.